The United Kingdom and the United States have secured a landmark trade agreement that will guarantee zero import taxes on British drug products entering the US market.
The Terms of the Deal
As part of the deal, the UK has committed to raise funding on pharmaceuticals through the National Health Service (NHS). This pledge secures that duties on these key goods will be held at zero for a period of the next three years.
This deal comes after recent threats to hike tariffs on branded drug imports, with potential rates floated up to one hundred percent.
"This agreement between the United Kingdom strengthens the international landscape for cutting-edge drugs and brings long-overdue balance to transatlantic medicine commerce," a release declared.
Commercial Impact
Pharmaceuticals constitute one of the Britain's biggest goods shipped to the United States, which is by far the largest buyer for leading UK drugmakers.
Trade data reveal that in the one-year period leading up to last September, the UK exported pharmaceutical products worth billions to the US. This value accounted for 17.4% of all goods exports in that timeframe.
"This deal secures work, stimulates funding and sets the stage for the UK to establish itself as a global hub for life sciences," a government official commented.
Specific NHS Changes
The agreement involves several notable changes from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The sum manufacturers must return to the NHS to stay within budget will be limited at 15%. In the past, rebates topped 20%.
Industry Background
This agreement follows a ongoing row between the pharmaceutical industry and the ministers over medicine costs and approval rates.
This friction were heightened by assertions that US consumers were paying several times more for the same drugs than patients in the other developed nations.
Recently, several large manufacturing plans in the UK have been delayed or scrapped, while substantial expansions have been pledged toward American operations.
One official publicly accepted that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had declined as a percentage of its overall budget over the last ten years.
